These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 36328301)

  • 1. Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy.
    Peng X; Pan W; Jiang F; Chen W; Qi Z; Peng W; Chen J
    Pharmacol Res; 2022 Dec; 186():106529. PubMed ID: 36328301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Opportunity for "Old" Molecules: Targeting PARP1 Activity through a Non-Enzymatic Mechanism.
    Iglesias P; Seoane M; Golán-Cancela I; Fraga M; Arce VM; Costoya JA
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC-targeting epigenetic modulators for cancer immunotherapy.
    Cheng B; Pan W; Xiao Y; Ding Z; Zhou Y; Fei X; Liu J; Su Z; Peng X; Chen J
    Eur J Med Chem; 2024 Feb; 265():116129. PubMed ID: 38211468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A PARP1-TIMELESS alliance in cancer therapy.
    Tarsounas M
    Mol Cell; 2024 May; 84(10):1824-1825. PubMed ID: 38759623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone ADP-ribosylation promotes resistance to PARP inhibitors by facilitating PARP1 release from DNA lesions.
    Zentout S; Imburchia V; Chapuis C; Duma L; Schützenhofer K; Prokhorova E; Ahel I; Smith R; Huet S
    Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2322689121. PubMed ID: 38865276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer.
    Li G; Lin SS; Yu ZL; Wu XH; Liu JW; Tu GH; Liu QY; Tang YL; Jiang QN; Xu JH; Huang QL; Wu LX
    Biochem Pharmacol; 2022 Dec; 206():115329. PubMed ID: 36309080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisiting PARP2 and PARP1 trapping through quantitative live-cell imaging.
    Zhang H; Lin X; Zha S
    Biochem Soc Trans; 2022 Aug; 50(4):1169-1177. PubMed ID: 35959996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Update on Poly(ADP-ribose) Polymerase I-A Brief Review.
    Negi P; Lakshmanan K; Patel PK; Rajagopal K; Byran G
    Mini Rev Med Chem; 2023; 23(18):1762-1771. PubMed ID: 36824002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities.
    Hu X; Zhang J; Zhang Y; Jiao F; Wang J; Chen H; Ouyang L; Wang Y
    Eur J Med Chem; 2022 Feb; 230():114094. PubMed ID: 34998039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of a tumor-selective degrader of PARP1.
    Pu C; Wang S; Luo D; Liu Y; Ma X; Zhang H; Yu S; Lan S; Huang Q; Deng R; He X; Li R
    Bioorg Med Chem; 2022 Sep; 69():116908. PubMed ID: 35780655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of PARP1 in the DNA damage response and its application in tumor therapy.
    Wang Z; Wang F; Tang T; Guo C
    Front Med; 2012 Jun; 6(2):156-64. PubMed ID: 22660976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avoid the trap: Targeting PARP1 beyond human malignancy.
    Kim C; Chen C; Yu Y
    Cell Chem Biol; 2021 Apr; 28(4):456-462. PubMed ID: 33657415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
    Patel AG; Flatten KS; Schneider PA; Dai NT; McDonald JS; Poirier GG; Kaufmann SH
    J Biol Chem; 2012 Feb; 287(6):4198-210. PubMed ID: 22158865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
    Rajawat J; Shukla N; Mishra DP
    Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
    McGonigle S; Chen Z; Wu J; Chang P; Kolber-Simonds D; Ackermann K; Twine NC; Shie JL; Miu JT; Huang KC; Moniz GA; Nomoto K
    Oncotarget; 2015 Dec; 6(38):41307-23. PubMed ID: 26513298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PARP1 inhibitors: contemporary attempts at their use in anticancer therapy and future perspective].
    Wiśnik E; Ryksa M; Koter-Michalak M
    Postepy Hig Med Dosw (Online); 2016 Apr; 70():280-94. PubMed ID: 27117104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage.
    Gu Z; Pan W; Chen W; Lian Q; Wu Q; Lv Z; Cheng X; Ge X
    BMC Plant Biol; 2019 Aug; 19(1):364. PubMed ID: 31426748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-target inhibitors of PARP1 in cancer therapy: A drug discovery perspective.
    Zhang J; Zhang J; Li H; Chen L; Yao D
    Drug Discov Today; 2023 Jul; 28(7):103607. PubMed ID: 37146962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
    Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
    Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function.
    Feng FY; de Bono JS; Rubin MA; Knudsen KE
    Mol Cell; 2015 Jun; 58(6):925-34. PubMed ID: 26091341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.